Form 4: Bristol Myers Squibb Director Acquires Deferred Share Units

Bristol Myers Squibb Director Phyllis R. Yale acquired 776.053 Deferred Share Units, increasing her beneficial ownership to 37,734.687 units.

Summary

• Phyllis R. Yale, a Director of Bristol Myers Squibb Co. (BMY), acquired 776.053 Deferred Share Units (DSUs).
• The transaction date for this acquisition was September 30, 2025.
• Following this transaction, Ms. Yale beneficially owns a total of 37,734.687 Deferred Share Units.
• Each Deferred Share Unit is convertible into one share of Bristol Myers Squibb common stock upon settlement.
• Settlement of these units occurs when Ms. Yale ceases to be a director or at a future date she previously specified.
• The total beneficial ownership includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 7

Explanation: The acquisition of Deferred Share Units by a director is a positive signal of alignment with shareholder interests, though it is a routine compensation event rather than a discretionary purchase.

Positives

• The acquisition of Deferred Share Units by a director aligns their interests with those of shareholders, as the value of these units is tied to the company's stock performance.

Future Outlook

The Deferred Share Units will convert into shares of common stock upon the reporting person ceasing to be a director or at a future date previously specified by the reporting person.

Related Party Transactions

• The acquisition of Deferred Share Units by a director from the company constitutes a related-party transaction as part of the director's compensation.

Stakeholder Impact

• Shareholders may view the director's increased beneficial ownership through DSUs as a positive indicator of management's vested interest in the company's long-term performance.

Next Steps

• Settlement of the Deferred Share Units into common stock upon the director's departure or a pre-specified future date.

Key Dates

Recommendation

This Form 4 filing reports a routine acquisition of Deferred Share Units as part of a director's compensation. While it indicates alignment of interests, it is not a discretionary open-market purchase and does not provide new information significant enough to alter a fundamental investment recommendation for Bristol Myers Squibb.

Keywords

Bristol Myers Squibb, BMY, Form 4, Insider Transaction, Deferred Share Units, Director Compensation, Equity Compensation